Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs The Vita Coco Company Inc (COCO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs The Vita Coco Company Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while The Vita Coco Company Inc trades at $71.23 (market cap $4.08B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 9.8× The Vita Coco Company Inc's market cap, and The Vita Coco Company Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | COCO | |
|---|---|---|
Market Cap | $39.89B | $4.08B |
Sector | Health | Technology |
52-Week High | $491.22 | $84.02 |
52-Week Low | $278.09 | $32.30 |
Enterprise Value | $38.15B | $3.89B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Vita Coco (COCO) trades at $71.40, up 0.21% with a bullish technical signal supported by moving averages. The company demonstrates strong fundamentals with 37.4% gross margins and 26.32% ROE, though valuation metrics appear elevated with a P/E of 51.74. Recent Q1 2026 earnings beat expectations by 47%, while analysts maintain a 60% buy rating consensus with a $78 price target. The company is scheduled to report Q2 2026 results on July 23, 2026.
COCO presents growth potential driven by market leadership in coconut water and projected revenue expansion to $659M in 2026. However, premium valuation and competitive pressures in the beverage sector warrant caution. The stock's near-term catalyst will be Q2 earnings performance against the $0.56 EPS expectation, with technical support at $69 and resistance at $73.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About The Vita Coco Company Inc
The Vita Coco Company is a leading functional beverage brand specializing in coconut water. Its portfolio includes its flagship Vita Coco brand, clean energy drinks, and sustainable enhanced water products.
Read more on COCO →
